Latest Breaking News On - Colchicine lodoco - Page 1 : comparemela.com

Michael J. Blaha, MD, MPH, discusses his interpretation of the growing data detailing the role of inflammation as a driver of cardiovascular risk and how clinicians can identify patients who stand to benefit most from colchicine 0.5 mg tablets.

Paul ridkerMichaelj blahaNovartis corporationCiccarone centerBayer healthcare pharmaceuticalsDrug administrationAmerican college of cardiologyNovo nordiskClinical researchAmerican collegeCardiovascular disease preventionHeart diseaseJohns hopkinsColchicine lodocoMichael blahaAgepha pharma